Credit Suisse’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | $498M | Buy |
2,736,828
+101,696
| +4% | +$17.5M | 0.48% | 28 |
|
|
2023
Q4 | $408M | Sell |
2,635,132
-346,693
| -12% | -$50.5M | 0.39% | 39 |
|
|
2023
Q3 | $444M | Sell |
2,981,825
-15,309
| -0.5% | -$2.25M | 0.45% | 35 |
|
|
2023
Q2 | $404M | Buy |
2,997,134
+5,427
| +0.2% | +$796K | 0.4% | 38 |
|
|
2023
Q1 | $477M | Sell |
2,991,707
-263,199
| -8% | -$40.2M | 0.48% | 30 |
|
|
2022
Q4 | $526M | Buy |
3,254,906
+114,451
| +4% | +$17.5M | 0.56% | 24 |
|
|
2022
Q3 | $421M | Sell |
3,140,455
-62,003
| -2% | -$8.9M | 0.47% | 32 |
|
|
2022
Q2 | $490M | Sell |
3,202,458
-139,055
| -4% | -$21.2M | 0.51% | 28 |
|
|
2022
Q1 | $542M | Buy |
3,341,513
+13,623
| +0.4% | +$1.98M | 0.46% | 32 |
|
|
2021
Q4 | $451M | Sell |
3,327,890
-336,278
| -9% | -$39.7M | 0.24% | 63 |
|
|
2021
Q3 | $395M | Buy |
3,664,168
+182,734
| +5% | +$20.9M | 0.22% | 71 |
|
|
2021
Q2 | $391M | Sell |
3,481,434
-854,124
| -20% | -$96.2M | 0.21% | 72 |
|
|
2021
Q1 | $469M | Sell |
4,335,558
-149,061
| -3% | -$15.9M | 0.24% | 67 |
|
|
2020
Q4 | $481M | Sell |
4,484,619
-137,453
| -3% | -$13.2M | 0.24% | 80 |
|
|
2020
Q3 | $405M | Sell |
4,622,072
-152,914
| -3% | -$14.4M | 0.25% | 71 |
|
|
2020
Q2 | $469M | Buy |
4,774,986
+638,876
| +15% | +$56.3M | 0.34% | 51 |
|
|
2020
Q1 | $315M | Sell |
4,136,110
-1,502,724
| -27% | -$128M | 0.27% | 58 |
|
|
2019
Q4 | $499M | Sell |
5,638,834
-19,064
| -0.3% | -$1.58M | 0.36% | 43 |
|
|
2019
Q3 | $428M | Buy |
5,657,898
+2,917,243
| +106% | +$200M | 0.36% | 43 |
|
|
2019
Q2 | $199M | Buy |
2,740,655
+459,895
| +20% | +$36.1M | 0.18% | 102 |
|
|
2019
Q1 | $184M | Sell |
2,280,760
-1,029,202
| -31% | -$84.2M | 0.17% | 102 |
|
|
2018
Q4 | $305M | Buy |
3,309,962
+763,248
| +30% | +$67.1M | 0.32% | 57 |
|
|
2018
Q3 | $241M | Sell |
2,546,714
-95,645
| -4% | -$9.07M | 0.22% | 71 |
|
|
2018
Q2 | $245M | Sell |
2,642,359
-206,670
| -7% | -$20.2M | 0.24% | 61 |
|
|
2018
Q1 | $270M | Sell |
2,849,029
-297,943
| -9% | -$32.7M | 0.25% | 63 |
|
|
2017
Q4 | $304M | Sell |
3,146,972
-133,396
| -4% | -$12.6M | 0.27% | 62 |
|
|
2017
Q3 | $291M | Sell |
3,280,368
-192,552
| -6% | -$14.7M | 0.28% | 58 |
|
|
2017
Q2 | $252M | Sell |
3,472,920
-511,033
| -13% | -$34.4M | 0.25% | 79 |
|
|
2017
Q1 | $260M | Sell |
3,983,953
-254,579
| -6% | -$16M | 0.23% | 77 |
|
|
2016
Q4 | $265M | Sell |
4,238,532
-194,562
| -4% | -$11.9M | 0.26% | 61 |
|
|
2016
Q3 | $280M | Sell |
4,433,094
-183,652
| -4% | -$11.9M | 0.26% | 63 |
|
|
2016
Q2 | $286M | Buy |
4,616,746
+521,218
| +13% | +$31.8M | 0.32% | 50 |
|
|
2016
Q1 | $234M | Sell |
4,095,528
-797,961
| -16% | -$44.5M | 0.28% | 64 |
|
|
2015
Q4 | $290M | Sell |
4,893,489
-1,120,655
| -19% | -$64.5M | 0.33% | 51 |
|
|
2015
Q3 | $327M | Sell |
6,014,144
-367,573
| -6% | -$23.9M | 0.39% | 39 |
|
|
2015
Q2 | $429M | Buy |
6,381,717
+1,369,226
| +27% | +$89.4M | 0.42% | 34 |
|
|
2015
Q1 | $293M | Buy |
5,012,491
+758,962
| +18% | +$45.9M | 0.3% | 64 |
|
|
2014
Q4 | $278M | Sell |
4,253,529
-602,012
| -12% | -$38M | 0.25% | 75 |
|
|
2014
Q3 | $280M | Buy |
4,855,541
+538,963
| +12% | +$29.9M | 0.23% | 78 |
|
|
2014
Q2 | $244M | Buy |
4,316,578
+767,305
| +22% | +$40.3M | 0.2% | 91 |
|
|
2014
Q1 | $182M | Sell |
3,549,273
-16,167
| -0.5% | -$817K | 0.18% | 102 |
|
|
2013
Q4 | $188M | Buy |
3,565,440
+486,954
| +16% | +$23.9M | 0.17% | 102 |
|
|
2013
Q3 | $138M | Sell |
3,078,486
-276,211
| -8% | -$12.2M | 0.14% | 123 |
|
|
2013
Q2 | $139M | Buy |
+3,354,697
| New | +$147M | 0.14% | 113 |
|
Other funds holding ABBV
Credit Suisse's ABBV Position: Q1 2024 in Review
Credit Suisse increased its AbbVie (ABBV) stake by 3.9% in Q1 2024, buying an estimated $17.5M and bringing the position to 2,736,828 shares worth $498M. The position accounts for 0.48% of the portfolio, ranked #28.
Credit Suisse first reported a position in ABBV in Q2 2013 and has held it in 44 quarters since. The position peaked at $542M in Q1 2022. 3,379 funds tracked by Wall St. Rank hold ABBV as of Q1 2024.
- Credit Suisse held 2,736,828 shares of AbbVie worth $498M as of Q1 2024.
- Credit Suisse bought 101,696 AbbVie shares in Q1 2024, an estimated $17.5M.
- AbbVie made up 0.48% of Credit Suisse's portfolio in Q1 2024, its #28 holding.
- Credit Suisse first reported a position in AbbVie in Q2 2013 and has held it in 44 quarters since.
- Credit Suisse's AbbVie position peaked at $542M in Q1 2022.
- 3,379 funds tracked by Wall St. Rank held AbbVie as of Q1 2024.
Based on Credit Suisse's 13F filing for Q1 2024, filed 10 May 2024.